Reply to ‘Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis’

Documenti analoghi

• Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis
  di: Teppei Hagino, et al.
  Pubblicazione: (2025)
• Real world experience of switching from tralokinumab to lebrikizumab: Author's reply
  di: Teppei Hagino, et al.
  Pubblicazione: (2025)
• Comment on ‘Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity’ by Dupuis et al.
  di: Luca Potestio, et al.
  Pubblicazione: (2024)
• Single‐centre experience with tralokinumab in dupilumab‐experienced and naïve patients with atopic dermatitis
  di: Claire Fossati, et al.
  Pubblicazione: (2024)
• Effectiveness of dupilumab in tralokinumab‐resistant patients with atopic dermatitis: A real‐world experience from two referral centres
  di: Gianluca Tavoletti, et al.
  Pubblicazione: (2024)